The trading price of CytomX Therapeutics Inc (NASDAQ:CTMX) closed lower on Monday, July 07, and closing at $2.37, -5.20% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $2.355 and $2.47. The company’s P/E ratio in the trailing 12-month period was 4.78, while its 5Y monthly beta was 2.12. In examining the 52-week price action we see that the stock hit a 52-week high of $3.10 and a 52-week low of $0.40. Over the past month, the stock has lost -5.58% in value.
CytomX Therapeutics Inc, whose market valuation is $373.38 million at the time of this writing, is expected to release its quarterly earnings report on 2025-May-12. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest CTMX has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CTMX a recommendation rating is 4. Out of them, 1 rate it a Hold, while 3 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged CytomX Therapeutics Inc (CTMX) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that CTMX’s price is currently -2.98% off the SMA20 and 18.15% off the SMA50. The RSI metric on the 14-day chart is currently showing 52.58, and weekly volatility stands at 6.72%. When measured over the past 30 days, the indicator reaches 9.56%. CytomX Therapeutics Inc (NASDAQ:CTMX)’s beta value is currently sitting at 2.14. With analysts defining $3.25-$8 as the low and high price targets, we arrive at a consensus price target of $5.84 for the trailing 12-month period. The current price is about -37.13% off the estimated low and -237.55% off the forecast high, based on this estimate. Investors will be thrilled if CTMX’s share price rises to $5.84, which is the median consensus price. At that level, CTMX’s share price would be -146.41% below current price.
To see how CytomX Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: CTMX stock’s performance was -5.20% in the latest trading, and 130.10% in the past year. CytomX Therapeutics Inc has a P/E ratio of 4.78.
An evaluation of the daily trading volume of CytomX Therapeutics Inc (NASDAQ:CTMX) indicates that the 3-month average is 5.11 million. However, this figure has increased over the past 10 days to an average of 1.87.
Currently, records show that 157.54 million of the company’s shares remain outstanding. The insiders hold 33.99% of outstanding shares, whereas institutions hold 35.39%. The stats also highlight that short interest as of 2025-06-13, stood at 20.79 million shares, resulting in a short ratio of 4.32 at that time. From this, we can conclude that short interest is 1371.00 of the company’s total outstanding shares. It is noteworthy that short shares in June were up slightly from the previous month’s figure, which was 17.73 million. However, since the stock’s price has seen 79.55% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
